This After Market Study is Seeing if Dupilumab Plus Usual Standard of Care (SOC) is Better Than Usual Care Alone for Adult Participants After a Severe Chronic Obstructive Pulmonary Disease (COPD) Flare-Up Requiring Hospitalization

NCT07587658 · clinicaltrials.gov ↗

PHASE4

Phase

NOT_YET_RECRUITING

Status

754

Enrollment

INDUSTRY

Sponsor class

Conditions

Chronic Obstructive Pulmonary Disease (COPD)

Interventions

DRUG: dupilumab
DRUG: Placebo

Sponsor

Regeneron Pharmaceuticals

Collaborators

[object Object]